ESR1 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), presents a formidable challenge in terms of targeted therapy due to its lack of specific molecular targets.